<DOC>
	<DOCNO>NCT02157077</DOCNO>
	<brief_summary>The purpose current study evaluate ability Eylea induce regression PED height patient previously extensively treated Lucentis . The regimen propose study 3 monthly injection follow 6 week interval injection week 26 .</brief_summary>
	<brief_title>Aflibercept After Ranibizumab Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description>The regimen propose study 3 monthly injection follow 6 week interval injection week 26 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Men woman ≥ 50 year age Active primary subfoveal choroidal neovascularization ( CNV ) lesion secondary AMD include juxtafoveal lesion affect fovea evidence Fluorescein Angiography study eye Patient treat least 12 month Ranibizumab ( ≥ 8 injection ) Patient PED &gt; 250 µm , define spectral domain optical coherent tomography ( SDOCT ) , measure two consecutive visit inclusion persist sub retinal fluid baseline Patient affiliate social security scheme Signed Informed Consent Patient subfoveal atrophy and/or atrophy diameter great 150µm subfoveal juxtafoveal area Patient subfoveal fibrosis Subretinal hemorrhage either 50 percent total lesion area 1 disc area size study eye . Scar , fibrosis atrophy make &gt; 50 % total lesion study eye . Presence retinal pigment epithelial tear rip involve macula study eye . History vitreous hemorrhage within 4 week prior Visit 1 study eye . Presence cause choroidal neovascularization , include pathologic myopia ( spherical equivalent 8 diopter negative , axial length 25mm ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis study eye clinical evidence diabetic retinopathy , diabetic macular edema retinal vascular disease AMD either eye . Any history macular hole stage 3 study eye . Uncontrolled glaucoma ( defined intraocular pressure ≥25 mmHg despite treatment antiglaucoma medication ) prior laser treatment glaucoma study eye . Active intraocular inflammation uveitis scleritis episcleritis study eye ocular periocular infection either eye Presence history scleromalacia study eye . Aphakia pseudophakia absence posterior capsule ( unless occur result yttrium aluminum garnet ( YAG ) posterior capsulotomy ) study eye . Previous therapeutic radiation study eye . History corneal transplant corneal dystrophy study eye . Significant medium opacity , include cataract , study eye might interfere visual acuity , assessment toxicity , fundus photography . Any concurrent intraocular condition study eye ( e.g . cataract ) , opinion investigator , could require either medical surgical intervention 24 month study period . Any concurrent ocular condition study eye , opinion investigator , could either increase risk subject beyond expect standard procedure intraocular injection , otherwise may interfere injection procedure evaluation efficacy safety . Any systemic treatment investigational agent except dietary supplement vitamin past 6 month prior Day 1 condition . Any history allergy povidone iodine . Contraindications list Patient enrol another interventional research Patient already include study treatment one eye Pregnant nursing woman Lack effective contraception woman childbearing age</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Eye disease</keyword>
	<keyword>Vision Impairment Blindness</keyword>
	<keyword>Eyes Vision</keyword>
	<keyword>Seniors</keyword>
	<keyword>Neovascular Age-Related Macular Degeneration ( AMD )</keyword>
	<keyword>Retinal Disease</keyword>
</DOC>